Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

ReShape Lifesciences Appoints Thomas Stankovich as Chief Financial Officer
BiotechnologyCompany Update

ReShape Lifesciences Appoints Thomas Stankovich as Chief Financial Officer

October 30, 2019 8:00 AM

SAN CLEMENTE, CA / ACCESSWIRE / October 30, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment of Thomas Stankovich as Chief Financial Officer (CFO) effective immediately. "We are happy to have Tom join our senior leadership team as CFO," commented Bart Bandy, President and Chief Executive Officer of...

Read more
Xenetic Biosciences, Inc. to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
BiotechnologyConferences

Xenetic Biosciences, Inc. to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

October 29, 2019 7:05 AM

FRAMINGHAM, MA / ACCESSWIRE / October 29, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specific tumor neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic, will present at the Dawson James Securities 5th Annual Small...

Read more
Dyadic Announces New Collaboration with Leading Animal Health Company
BiotechnologyCompany Update

Dyadic Announces New Collaboration with Leading Animal Health Company

October 28, 2019 8:00 AM

JUPITER, FL / ACCESSWIRE / October 28, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global platform biotechnology company, announced today that it has entered into a fully funded collaboration with one of the leading animal health companies to demonstrate the C1 technology for expression and production of therapeutic proteins for companion and farm animal health diseases. Under the terms of the agreement, Dyadic...

Read more
Principal Investigator Dr. Jorge Hernando Ulloa Presents 6 Month VenoValve Data at the 20th Congress of Asian Society for Vascular Surgery
BiotechnologyCompany Update

Principal Investigator Dr. Jorge Hernando Ulloa Presents 6 Month VenoValve Data at the 20th Congress of Asian Society for Vascular Surgery

October 24, 2019 4:05 PM

VenoValve Patients Continue to Improve at 6 Months IRVINE, CA / ACCESSWIRE / October 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-human VenoValve study in Bogota, Colombia, presents new six (6) month VenoValve data at the 20th Congress of Asian...

Read more
Principal Investigator Dr. Jorge Hernando Ulloa to Present VenoValve Six Month Data at the 20th Congress of Asian Society for Vascular Surgery on October 25, 2019
BiotechnologyCompany Update

Principal Investigator Dr. Jorge Hernando Ulloa to Present VenoValve Six Month Data at the 20th Congress of Asian Society for Vascular Surgery on October 25, 2019

October 22, 2019 1:00 PM

IRVINE, CA / ACCESSWIRE / October 22, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Friday October 25, 2019, Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-man VenoValve® study in Bogota, Colombia, will present six month data on the VenoValve at the 20th Congress of Asian Society for Vascular Surgery....

Read more
Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate to Research the Therapeutic targeting of the DJ-1 Protein to Treat Immune Associated Diseases
BiotechnologyCompany Update

Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate to Research the Therapeutic targeting of the DJ-1 Protein to Treat Immune Associated Diseases

October 21, 2019 12:47 PM

Collaboration aims to explore the use of Cantabio's DJ-1 protein targeting small molecule drug candidates in immune associated diseases at Luxembourg Institute of Health PALO ALTO, CA / ACCESSWIRE / October 21, 2019 / Cantabio Pharmaceuticals, Inc. ("Cantabio" or the "Company"), a preclinical stage pharmaceutical company developing disease modifying therapeutics for Alzheimer's, Parkinson's and related neurological disorders, today announced...

Read more
Global Partners LP Raises Over $65,000 for Cure Rare Disease
BiotechnologyCompany Update

Global Partners LP Raises Over $65,000 for Cure Rare Disease

October 21, 2019 9:05 AM

Fueling groundbreaking development of precision medicine therapeutics to treat Duchenne muscular dystrophy and more. BOSTON, MA, / ACCESSWIRE / October 21, 2019 / Global Partners LP, a third-generation family-founded business, operating one of the largest networks of gas stations and convenience stores in the Northeast, announced today that it raised over $65,000 for Cure Rare Disease (CRD), a Boston-based non-profit organization committed to...

Read more
Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study
BiotechnologyCompany Update

Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study

October 21, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / October 21, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2b clinical trial evaluating the company's lead product candidate, EB01, as a monotherapy for patients with moderate to severe chronic allergic contact dermatitis (ACD). The U.S. Food and Drug Administration recently approved Edesa's clinical protocol and...

Read more
Great Bay Bio and Boji Medical have Reached Strategic Cooperation to Jointly Develop a Long-Acting Biological and Innovative Anti-Anemia Injection
BiotechnologyCompany Update

Great Bay Bio and Boji Medical have Reached Strategic Cooperation to Jointly Develop a Long-Acting Biological and Innovative Anti-Anemia Injection

October 18, 2019 3:25 AM

HONG KONG, CHINA / ACCESSWIRE / October 18, 2019 / Great Bay Bio, a leading AI biotechnology company dedicated to big data-driven CMC (Chemistry Manufacturing and Controls) development of innovative biologics, is pleased to announce that a strategic cooperation was reached with Guangzhou Boji Medical Biotechnological Co., Ltd. (hereinafter referred to as "Boji Medical ") to jointly develop GBB101, a new long-acting injectable biologics for the...

Read more
Mymetics Announces New Study to Predict Efficacy of Second- Generation COP Allergy Immunotherpy with Virosomes
BiotechnologyCompany Update

Mymetics Announces New Study to Predict Efficacy of Second- Generation COP Allergy Immunotherpy with Virosomes

October 17, 2019 6:00 AM

- The second-generation Allergen Immunotherapy based on Anergis Continous Overlapping Peptides (COP) linked to Mymetics Virosomes will be tested by Stallergenes Greer using its therapeutic model of birch allergy - Results of the study are expected in Q1 2020 EPALINGES, SWITZERLAND / ACCESSWIRE / October 17, 2019 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines and...

Read more
Xenetic Biosciences, Inc. to Present at BIO Investor Forum
BiotechnologyCompany Update

Xenetic Biosciences, Inc. to Present at BIO Investor Forum

October 16, 2019 8:05 AM

Presentation with Live Audio Webcast on Wednesday, October 23rd at 2:45 PM PT FRAMINGHAM, MA / ACCESSWIRE / October 16, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specific tumor neoantigens, announced today that Jeffrey Eisenberg, Chief Executive...

Read more
Hancock Jaffe to Present at the Inaugural MicroCap Rodeo Investor Conference on October 16, 2019
BiotechnologyConferences

Hancock Jaffe to Present at the Inaugural MicroCap Rodeo Investor Conference on October 16, 2019

October 14, 2019 12:15 PM

IRVINE, CA / ACCESSWIRE / October 14, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has been invited to present at the inaugural MicroCap Rodeo Investor Conference on October 16, 2019 in Austin. The MicroCap Rodeo Investor Conference is being held October 15-16, 2019 at the Hilton Austin in Austin, Texas. Hancock Jaffe CEO Rob Berman is scheduled...

Read more
Dyadic to Attend Three Upcoming Investor Conferences in October
BiotechnologyConferences

Dyadic to Attend Three Upcoming Investor Conferences in October

October 10, 2019 8:30 AM

JUPITER, FL / ACCESSWIRE / October 10, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive...

Read more
Wellmetrix and DSM Announce Research Partnership to Assess Diagnostic Platform for Personalized Nutrition
BiotechnologyCompany Update

Wellmetrix and DSM Announce Research Partnership to Assess Diagnostic Platform for Personalized Nutrition

October 8, 2019 11:05 AM

KEEGO HARBOR, MI / ACCESSWIRE / October 8, 2019 / Personal health testing developer Wellmetrix and Royal DSM, a purpose-led, global science-based company active in Nutrition, Health and Sustainable Living, have announced a research partnership to explore the use of Wellmetrix's diagnostic platform to perform non-invasive and point-of-need measurements of key health biomarkers as part of a nutrition intervention using combinations of DSM's...

Read more
Xenetic Biosciences, Inc. Provides Business Outlook
BiotechnologyCompany Update

Xenetic Biosciences, Inc. Provides Business Outlook

October 8, 2019 8:30 AM

Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders Management working with KOLs and subject matter experts to formalize XCART development plan Completion of recent financing expected to fund operations through key development milestones Proprietary technology, PolyXen™, expected to generate royalties as early as Q4 2019 FRAMINGHAM, MA /...

Read more
Angle PLC Annouces Notice of AGM
BiotechnologyRegulatory

Angle PLC Annouces Notice of AGM

October 8, 2019 2:00 AM

Notice of AGM and Posting of Annual Report and Accounts GUILDFORD, SURREY / ACCESSWIRE / October 8, 2019 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company, announces that its AGM will be held at 2:00 pm on Wednesday 30 October 2019 at ANGLE plc, 10 Nugent Road, Surrey Research Park, Guildford, GU2 7AF. The Annual Report and Accounts for the year ended 30 April 2019, were posted to shareholders on 7 October 2019,...

Read more
Late-Stage Data from Abicipar in Age-Related Macular Degeneration to be Showcased at American Academy of Ophthalmology (AAO) Annual Meeting
BiotechnologyInvestor Relations

Late-Stage Data from Abicipar in Age-Related Macular Degeneration to be Showcased at American Academy of Ophthalmology (AAO) Annual Meeting

October 4, 2019 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 4, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that its partner Allergan plc, (NYSE:AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology, will present new data from investigational Abicipar at the Annual Meeting of the American Academy...

Read more
American CryoStem Expands Investigator Team with Sub-Investigators for Post Concussive Syndrome IND
BiotechnologyCompany Update

American CryoStem Expands Investigator Team with Sub-Investigators for Post Concussive Syndrome IND

October 3, 2019 6:00 AM

The Company and the Principal Investigator announce the addition of sub-investigators to the clinical trial team with extensive experience assessing and treating athletes and military personnel suffering from concussion injury, traumatic brain injury and Post Concussion Syndrome EATONTOWN, NJ / ACCESSWIRE / October 3, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented...

Read more
Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy
BiotechnologyInvestor Relations

Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy

October 3, 2019 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 3, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that the first patient has been enrolled and dosed in a Phase 1 first-in-human study of MP0310 as a single agent in patients with advanced solid tumors. The trial, entitled MP0310-CP101, will evaluate the optimal dose range of MP0310...

Read more
Vitro Biopharma 3rd Quarter ended July 31st 2019 Financial Results of Operations
BiotechnologyCompany UpdateEarningsFinancingInvestor RelationsProduct Announcements

Vitro Biopharma 3rd Quarter ended July 31st 2019 Financial Results of Operations

September 26, 2019 12:00 PM

GOLDEN, CO / ACCESSWIRE / September 26, 2019 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 3rd quarter ended September 24th 2019 financial results of operations. Vitro Diagnostics Inc. ("Vitro Biopharma") is pleased to announce a record 3rd quarter in Stem Cell Revenues. Vitro Biopharma recorded 3rd quarter revenues of $225,191 vs $141,783 an increase of 59% over the same comparative quarter last year. Current...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?